我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

法舒地尔治疗冠状动脉慢血流的疗效及对氧化应激的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第4期
页码:
435-438
栏目:
临床研究
出版日期:
2017-02-25

文章信息/Info

Title:
Curative effect of fasudil in treatment of coronary slow flow and its effects on oxidative stress
作者:
国 伟1; 刘力文1; 吴苏宁1; 张亚男1; 王 盟2; 伊 忻3
济宁市第一人民医院：1.老年医学科，2.药学部，3.医学检验科，山东 济宁272011
Author(s):
GUO Wei1;  LIU Li-wen1;  WU Su-ning1;  ZHANG Ya-nan1;  WANG Meng2;  YI Xin3
1.Department of Geriatrics, 2.Department of Pharmacy, 3.Clinical Laboratory, Jining First People’s Hospital, Jining 272011, Shandong, China
关键词:
冠状动脉慢血流; 盐酸法舒地尓; 氧化应激; 丙二醛; 晚期糖基化终产物; 超氧物歧化酶; 谷胱甘肽转移酶
Keywords:
acute coronary syndrome;  fasudil; oxidative stress;  malondialdehyde;  advanced glycation end products;  superoxidc dismutase;  glutathione S-transferase
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨盐酸法舒地尔对冠状动脉慢血流(coronary slow flow,CSF)患者的治疗作用及对血浆中机体氧化应激指标丙二醛（MDA）、晚期糖基化终产物（AGEs）、超氧物歧化酶（SOD）、谷胱甘肽转移酶（GST）水平的影响。方法 选择因胸痛住院行冠状动脉造影检查显示结果正常但存在着CSF现象的患者82例，随机分为法舒地尔组与常规治疗组，每组患者均为41例。常规治疗组给予拜阿司匹林、阿托伐他汀、硝酸酯类等常规治疗；法舒地尔组在常规治疗基础上给予盐酸法舒地尔治疗。观察治疗前、后2周两组患者心绞痛疗效、冠状动脉血流速度TIMI计帧以及血浆MDA、AGEs、SOD和GST水平的变化。结果 法舒地尔组治疗后患者心绞痛疗效总有效率为88%，常规治疗组为66%，差异有统计学意义(P<0.05)。法舒地尔组治疗后患者冠状动脉血流TIMI计帧显著低于治疗前及常规治疗组治疗后（均P<0.01）。两组治疗前MDA、AGEs、SOD、GST水平的比较差异均无统计学意义。法舒地尔组与常规治疗组治疗后血浆MDA、AGEs水平均显著低于本组治疗前（均P<0.01）。法舒地尔组与常规治疗组治疗后血浆SOD、GST水平均显著高于本组治疗前（均P<0.01）。法舒地尔组治疗后血浆MDA、AGEs水平均较常规治疗组治疗后显著下降(均P<0.01)。法舒地尔组治疗后血浆SOD、GST水平均较常规治疗组治疗后显著升高(均P<0.01)。结论 法舒地尔治疗CSF的疗效优于常规治疗组，法舒地尔可能通过抑制机体氧化应激反应的机制发挥作用。
Abstract:
AIM To investigate the efficacy of fasudil in the treatment of coronary slow flow (CSF) and its effect on plasma oxidative stress indexes: MDA, AGEs, SOD and GST. METHODS Eighty-two CSF patients with normal coronary angiography were randomly divided into conventional treatment group and fasudil group, 41 cases ineach group. Another 40 patients with normal coronary angiography served as control group. Patients in the conventional treatment group were given conventional treatment (aspirin, nitrates and simvastatin), while patients in the fasudil group were given fasudil on the basis of the conventional treatment. Angina pectoris, TIMI and levels of plasma MDA, AGEs, SOD and GST of the brachial artery were observed in the three groups before and two weeks after treatment. RESULTS The total effective rate in the fasudil group was higher than that in the control group (88% vs. 66%, P<0.05). TIMI improved significantly in the fasudil group after treatment compared with that before treatment and with that in the conventional group after treatment (P<0.01). The peripheral blood levels of MDA and AGEs in the CSF group at the beginning of treatment were significantly higher than those in the normal control group (P<0.01). The peripheral blood levels of SOD and GST in CSF group at the beginning of treatment were significantly reduced compared with those in the normal control group (P<0.01). The peripheral blood levels of MDA and AGEs in the fasudil treatment group and conventional therapy group were all significantly reduced compared with those in the normal control group (P<0.01). The peripheral blood levels of SOD and GST in the fasudil treatment group and conventional therapy group were all significantly higher than those in the normal control group (P<0.01). No difference in pre-treatment MDA, AGEs, SOD and GST were found between the two groups (P>0.05). The pre-treatment MDA and AGEs levels in fasudil treatment group were significantly reduced compared with those in the conventional therapy group (P<0.01). The pre-treatment SOD and GST levels in the fasudil treatment group were significantly higher than those in the conventional therapy group (P<0.01). CONCLUSION Oxidative stress may play a key role in the pathophysiology of CSF. Fasudil improves the curative effect of coronary slow flow by inhibiting oxidative stress.

参考文献/References

[1]Tambe AA,Demany MA,Zimmennan HA,et al.Angina pectoris and slow flow velocity of dye in　coronary arteries:a new angiographic finding[J].Am Heart J,1972,84(1):66-71.
[2]Wang X,Nie SP.The coronary slow flow phenomenon: characteristics,mechanisms and implications[J].Cardiovasc Diagn Ther,2015,1(l):37-43.
[3]Nunes KP,Rigsby CS,Webb RC.Rho A/Rho-kinase and vascular diseases: what is the link[J].Cell Mol Life Sci,2014,67(22):3823-3836.
[4]谢 进，李 欣，胡 刚，等.盐酸法舒地尔对心绞痛患者冠状动脉慢血流的疗效[J].微循环杂志,2012-22:38-41.
[5]Yucel H,Ozaydin M,Dogan A,et al.Evaluation of plasma oxidative status in patients with slow coronary flow[J].Kardiol Pol,2013,71(6):588-594.
[6]闫丽英,张风雷,袁 燕,等.冠状动脉慢血流与氧化应激的临床研究[J].临床心血管病杂志,2016,32(4):351-354.
[7]Baykal T,Seferoglu B, Karsan O, et al. Antioxidant profile in patients with complex regional pain syndrome type I[J].Int J Rheum Dis,2014,17(2):156-158.
[8]Bansal S,Siddarth M,Chawla D,et al.Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro[J].Mol Cell Biochem,2012,(361):289-296.
[9]Sotsuka T,Ibuki C,Suzuki T,et al.Administration of the Rho-kinase inhibitor, fasudil,following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina[J].Coron Artery Dis,2014,19(2):105-110.
[10]Celermajer DS,Sorensen KE,Gooch VM,et al.Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis[J].Lancet,1992,340(8828):1111-1115.

备注/Memo

备注/Memo:
收稿日期：2016-07-10.基金项目：济宁市医药卫生科技发展计划项目资助（2015-57-109 ） 通讯作者：伊忻，主管技师，主要从事心血管疾病基础与临床技术研究 Email：lnyxkgw@163.com 作者简介：国伟，主治医师，博士 Email：guowei19811207@163.com
更新日期/Last Update: 1900-01-01